TRAX First Tracks Biotherapeutics, Inc. - Ordinary Shares
$45.47
Price · Aug 19, 2026
Fundamentals as of Aug 12, 2026
52W Range
$15–$50
88% of range
Analyst Rating
BUY
14 analysts
Price Target
$63
+39% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—
TRAX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$45.47
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$15 – $50
TRAX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
TRAX
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
TRAX
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
TRAX
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
TRAX
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
TRAX
Peer Median
TRAX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
14 analysts
- Strong Buy 4 28.6%
- Buy 9 64.3%
- Hold 1 7.1%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
8 analysts · 2026-08-17
Median
$65.00
Now
$45.47
Low
$30.00
High
$95.00
Median target
$65.00
+43.0%
Mean target
$63.38
+39.4%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-0.92%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| March 31, 2026 | $-1.45 | $-0.53 | -0.92% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| TRAX | — | — | — | — | — | — |
| FBRX | $353M | -5.8 | 106.6% | -2555.2% | -86.9% | — |
| ZYME | $1.97B | -24.4 | 38.9% | -76.6% | -26.9% | — |
| BCAX | $953M | -6.7 | — | — | -33.0% | — |
| XNCR | $1.10B | -12.3 | 13.7% | -73.2% | -14.0% | — |
| ABSI | $529M | -4.2 | -38.2% | -4113.7% | -63.5% | — |
| TYRA | $1.41B | -13.1 | — | — | -42.7% | — |
| VIR | $841M | -1.9 | -7.6% | -638.9% | -51.1% | — |
| JBIO | $761M | -4.8 | — | — | -47.7% | — |
| AVBP | $854M | -4.7 | — | — | -59.7% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Balance Sheet 19
| Metric | Trend | 2025 |
|---|---|---|
| Cash & Equivalents | $238M | |
| Prepaid Expense | $5M | |
| Other Current Assets | $2M | |
| Current Assets | $316M | |
| PP&E (Net) | $1M | |
| PP&E (Gross) | $9M | |
| Accum. Depreciation | $7M | |
| Other Non-current Assets | $256.0K | |
| Total Assets | $331M | |
| Accounts Payable | $3M | |
| Accrued Liabilities | $26M | |
| Current Liabilities | $31M | |
| Capital Leases | $12M | |
| Common Stock | $0 | |
| Retained Earnings | $0 | |
| AOCI | $-24.0K | |
| Stockholders' Equity | $287M | |
| Liabilities + Equity | $331M | |
| Shares Outstanding | 0 |
Income Statement 11
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| R&D Expense | $26M | $34M | |
| SG&A Expense | $9M | $19M | |
| Operating Expenses | $35M | $53M | |
| Operating Income | $-35M | $-53M | |
| Other Non-op | $-1.0K | $-1.0K | |
| Net Income | $-33M | $-50M | |
| EPS (Basic) | $-0.95 | · | |
| EPS (Diluted) | $-0.95 | · | |
| Shares (Basic) | 35,003,000 | · | |
| Shares (Diluted) | 35,003,000 | · | |
| EBITDA | $-35M | $-53M |
Balance Sheet 19
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Cash & Equivalents | $168M | $248M | |
| Prepaid Expense | $10M | $3M | |
| Other Current Assets | $2M | · | |
| Current Assets | $178M | $289M | |
| PP&E (Net) | $1M | $1M | |
| PP&E (Gross) | $8M | $8M | |
| Accum. Depreciation | $7M | $7M | |
| Other Non-current Assets | $0 | $0 | |
| Total Assets | $183M | $291M | |
| Accounts Payable | $3M | $7M | |
| Accrued Liabilities | $7M | $26M | |
| Current Liabilities | $12M | $33M | |
| Capital Leases | $2M | $0 | |
| Common Stock | $35.0K | · | |
| Retained Earnings | $-25M | · | |
| AOCI | $0 | $-146.0K | |
| Stockholders' Equity | $169M | $257M | |
| Liabilities + Equity | $183M | $291M | |
| Shares Outstanding | 35,390,679 | · |
Cash Flow 9
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| D&A | $105.0K | $125.0K | |
| Stock-based Comp | $8M | $12M | |
| Other Non-cash | · | $6M | |
| Operating Cash Flow | $-32M | $-33M | |
| CapEx | $25.0K | $17.0K | |
| Investing Cash Flow | $-25.0K | $35M | |
| Financing Cash Flow | $-49M | $8M | |
| Net Change in Cash | $-80M | $10M | |
| Free Cash Flow | · | $-33M |
Profitability 2
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| ROA | -36.4% | -34.8% | |
| ROE | -39.5% | -39.2% |
Liquidity & Solvency 2
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Current Ratio | 14.3 | 8.7 | |
| Quick Ratio | 13.5 | 7.5 |
Valuation (TTM) 3
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Market Cap | $712M | · | |
| P/B | 4.2 | · | |
| P / Tangible Book | 4.2 | · |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Company insiders 10 insiders · 3 officers · 7 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Daniel Faga | President, CEO | Aug. 15, 2026 A | — | 0 | 0 | $0 |
| Benjamin Stone | Chief Business Officer | Aug. 15, 2026 A | — | 0 | 0 | $0 |
| Lizzul Paul F. | Chief Medical Officer | Aug. 15, 2026 A | — | 0 | 0 | $0 |
| Anthony J. Ware | Director | June 15, 2026 M | 15,660 | 0 | 0 | $0 |
| Rita Jain | Director | June 15, 2026 M | 19,194 | 0 | 0 | $0 |
| Magda Marquet | Director | June 15, 2026 M | 15,960 | 0 | 0 | $0 |
| John P. Schmid | Director | June 15, 2026 M | 37,652 | 0 | 0 | $0 |
| John A Orwin | Director | June 15, 2026 M | 16,695 | 0 | 0 | $0 |
| Dennis M Fenton | Director | June 15, 2026 M | 10,995 | 0 | 0 | $0 |
| EcoR1 Capital, LLC | 10% owner | April 20, 2026 S | 3,174,519 | 0 | 1 | $-64,983,991 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 18 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.56% | 35,833 SH | Aug. 8, 2026 | Daily |
| IWC · iShares Trust | 0.24% | 79,198 SH | Aug. 8, 2026 | Daily |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.11% | 1,899 SH | Aug. 8, 2026 | Daily |
| IWO · iShares Trust | 0.05% | 147,073 SH | Aug. 8, 2026 | Daily |
| IWM · iShares Trust | 0.03% | 595,656 SH | Aug. 8, 2026 | Daily |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.03% | 20,643 SH | Aug. 8, 2026 | Daily |
| ISCB · iShares Trust | 0.02% | 1,448 SH | Aug. 8, 2026 | Daily |
| IWN · iShares Trust | 0.02% | 68,008 SH | Aug. 8, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.02% | 17,459 SH | Aug. 8, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 309,191 SH | Aug. 8, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.01% | 134,320 SH | Aug. 8, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.01% | 6,100 SH | Aug. 8, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.01% | 73,220 SH | Aug. 8, 2026 | Daily |
| WSML · iShares Trust | 0.01% | 1,335 SH | Aug. 8, 2026 | Daily |
| ITOT · iShares Trust | 0.00% | 45,833 SH | Aug. 8, 2026 | Daily |
| IWV · iShares Trust | 0.00% | 7,386 SH | Aug. 8, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 1,111,470 SH | Aug. 8, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 2,297 SH | Aug. 8, 2026 | Daily |